Virtual Reality in Hemodialysis to Improve Psychological Well-being

Running, not enrolling · Not applicable · Has a placebo group

Conditions studied: End Stage Kidney Disease, Depressive Symptoms

In brief

The long-term goal is to create behavioral health technologies to advance the science that leverages state-of-the-art technology to delivery psychotherapeutic treatment to individuals on hemodialysis (HD) to improve their emotional well-being, quality of life, and overall health. The objective in this small R01 study is to design a virtual reality (VR) platform, that fully immerses users into a fictitious lifelike environment, to deliver an evidence-based positive psychological intervention and to test whether it improves the emotional well-being of individuals on HD with comorbid depression. In this proposed 2-arm randomized controlled trial, the investigators hypothesize that delivery of psychotherapy in individuals on HD using a VR environment will prove feasible and will result in significant improvements in depressive symptoms, quality of life, and treatment adherence, along with reduced rates of hospitalization when compared to an active control condition-all while serving as a cost-effective and far-reaching platform for expansive dissemination. The Specific Aims are: Aim #1: To develop VR software to immersively deliver the skills taught in a 5-week evidence-based positive psychological intervention in individuals on HD to improve their emotional well-being. Aim #2: To evaluate the acceptability and feasibility of a 5-week positive psychological intervention, delivered using a VR platform through consideration of rates of recruitment, refusal, retention, (non)compliance, and adherence. Aim #3: To test initial efficacy of the VR-based psychotherapeutic intervention, compared to a control arm, on outcomes of depression, psychological well-being, quality of life, treatment adherence, HD sessions missed, and hospitalizations in HD patients. Knowledge gained from completion of the proposed research will result in the first VR software application to deliver psychotherapy to individuals on HD, while simultaneously allowing them to leave the confines of the clinic and virtually travel to distant regions of the world. This new therapeutic approach can be used to successfully address the added burden of psychological distress experienced by individuals on HD, with the potential to positively impact their quality of life, engagement in healthful behaviors, and overall healthy longevity. And, these findings will yield data essential for a fully-powered trial testing important health outcomes and biomarkers in individuals on HD.

Key facts

Study ID

NCT05642364

Run by

University of Illinois at Urbana-Champaign

People needed

61

Starts

2023-06-22

Expected to finish

2026-03-31

Last updated by the study team

2026-02-18

Who can join

Age: 21 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• 1) HD patient with at least three months since treatment initiation
• 2) Beck Depression Inventory-II (BDI-II) score ≥11
• 3) age 21 or older
• 4) visual and audio acuity to immerse in our VR world
• 5) fluent in English or Spanish

You may not qualify if…

• 1) unavailable for study period
• 2) prevalent cognitive impairment denoting dementia
• 3) physical limitation restricting use of a head-mounted display
• 4) history of epilepsy, seizures, or vertigo.

Where it is running

• DaVita Little Village Dialysis PD — Chicago, Illinois, United States
• UI Health - Dialysis Unit, EEI Suite 2028 — Chicago, Illinois, United States
• DaVita Garfield Kidney Center — Chicago, Illinois, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.